A stakeholder informed randomized trial of pretest video education VS standard genetic counseling for cancer patients: evaluating the impact on patients, providers and practices

Ended Project Grant Awarded Last action

Award ID
R01HG011928
Recipient
Awarding agency
Obligated
$7,386,734

Award facts

Assistance listing
93.172 Human Genome Research
Completion date
Funding
  • $5,694,527.00 Federal
  • $1,692,207.00 Non-federal
Place of performance
Boston, MA 02215, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Despite the well-established benefits of germline genetic testing (GGT) for cancer patients including informing treatment (targeted therapies, appropriate surgery) and family members (cascade testing), there has been inconsistent integration of GGT into oncology workflows leading to significant gaps in care. Less labor- intensive, streamlined service delivery strategies may improve access to testing for and reduce the burden on sick cancer patients particularly in less resource-rich environments. This proposal is directly responsive to RFA-HG-20-048 because IT measures the efficacy and acceptability of novel genetic counseling practices aimed at modernizing genetics care. The overall objectives in this application are to refine our pretest cancer genetics video education and result-dependent disclosure (verdi) intervention, compare patient-centered outcomes of verdi to standard counseling, elucidate required resources / costs and delineate the receptivity and readiness for implementation of verdi by genetic counselors (GCS). The rationale for the proposed research is that alternative models must be informed by rigorous evaluation of effects on patients and GCS. These goals will be accomplished by pursuing three specific aims: (i) refine and adapt verdi to ensure acceptability among diverse cancer patients (II) conduct a randomized trial of verdi VS standard genetic counseling care through two cancer centers and their community partners and compare patient-centered outcomes and (III) evaluate the impact of the verdi paradigm on GCS and costs to inform practice. In aims 1 and 2, the studies will include patients of diverse backgrounds in several settings with cancers for which GGT is standard and those for which IT is less routine. Qualitative interviews of patients will inform the refinement of verdi, followed by a randomized trial of verdi VS standard of care genetic counseling with measurement of the following patient-centered outcomes: receipt of intervention, testing uptake, satisfaction, psychosocial impact, knowledge and family communication. Aim 3 will use a mixed-methods analysis through semi- structured qualitative interviews followed by a national survey of GCS to elucidate facilitators and barriers to widespread implementation. Under this aim, a cost analysis evaluating cost-per-patient tested will be performed using data collected during the randomized trial. The research proposed in this application is innovative because IT uses simple, adaptable technology combined with a pragmatic, patient-centered approach informed by the needs of diverse patients to standardize processes. Robust outcomes of all stakeholders, especially GCS whose role would change the most are measured. The proposed research is significant because IT is expected to provide patient, provider and systems level data to inform ways to expand access to GGT and counseling for ILL patients safely and effectively. Ultimately, this knowledge will foster scalable approaches to genetic and genomics care for a variety of medical conditions, address the evolving role of GCS while promoting improved access and delivering on the promise of personalized care.

Transactions

Action Federal Non-federal Date
Amendment $723,445 $0
Amendment $793,334 $0
Amendment $793,334 $0
Amendment $838,005 $0
Amendment $838,005 $838,005
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $854,202 $0
Original award $854,202 $854,202

Subawards

Subrecipient Amount Awarded
Georgetown University Project Title: A Stakeholder Informed Randomized Trial of Pretest Video Education vs Standard Genetic Counseling for Cancer Patients: Evaluating the Impact on… $39,059
Rutgers, The State University Of New Jersey Throughout the duration of the Subaward Project Description: project (years 1-4), Deborah Toppmeyer, MD and team will provide the following: YEAR 1: Staff… $147,903
MNW Consulting Group, LLC Throughout the duration of the project (years 1-4), Sarah McGraw, PhD (Co-Investigator) will provide the following, in conjunction with a Clinical Research… $19,829

Quick answers

Who received award R01HG011928?

R01HG011928 was awarded to Dana-Farber Cancer Institute, Inc. by National Human Genome Research Institute (National Institutes of Health) on September 22, 2021.

How much is award R01HG011928 worth?

$7,386,734 has been obligated on R01HG011928: $5,694,527 in federal funding and $1,692,207 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login